title: The rise and fall of atrial natriuretic peptide for acute renal failure.
abstract: Atrial natriuretic peptide can increase glomerular filtration rate and filtration fraction and can promote natriuresis, effects that would logically seem to improve renal function after acute tubular necrosis from ischemic or toxic injury. Early human trials suggested a beneficial effect of atrial natriuretic peptide on creatinine clearance, and a reduction in the need for dialysis in treated patients. However, randomized, placebo-controlled trials have failed to show a clinically relevant benefit on survival, dialysis-free survival, or renal function in patients treated with this agent.
authors.affiliation: Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.
authors.forename: R M
authors.initials: RM
authors.lastname: Brenner
authors.forename: G M
authors.initials: GM
authors.lastname: Chertow
mesh_terms: D058186:Acute Kidney Injury / Q000188:drug therapy*; D009320:Atrial Natriuretic Factor / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D016032:Randomized Controlled Trials as Topic
chemical_list: D009320:Atrial Natriuretic Factor